Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Debois · SciRah

Researcher profile · Semantic Scholar

M. Debois

Share profile

M. Debois — researcher profile on SciRah

h-index: 23
Works: 49
Citations: 2,952

Most-cited papers

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
J. Vansteenkiste, B. Cho, T. Vanakesa, T. De Pas +26 more
2016The Lancet Oncology427 citations Open access
Semantic Scholar
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
U. Studer, P. Whelan, W. Albrecht, J. Casselman +7 more
2006Journal of Clinical Oncology347 citations
Semantic Scholar
Long-term Survival and Metastatic Pattern of Pancreatic and Periampullary Cancer After Adjuvant Chemoradiation or Observation: Long-term Results of EORTC Trial 40891
Hans G. Smeenk, C. V. van Eijck, W. Hop, J. Erdmann +6 more
2007Annals of Surgery289 citations
Semantic Scholar
Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer
C. Sternberg, P. Whelan, J. Hetherington, B. Paluchowska +10 more
2005Oncology205 citations
Semantic Scholar
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
C. Köhne, J. De Grève, J. Hartmann, I. Láng +16 more
2008Annals of Oncology161 citations Open access
Semantic Scholar
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
B. Dréno, John F. Thompson, B. M. Smithers, M. Santinami +34 more
2018The Lancet Oncology159 citations Open access
Semantic Scholar
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
U. Studer, L. Collette, P. Whelan, W. Albrecht +7 more
2008European Urology151 citations
Semantic Scholar
Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group
G. Oosterhof, J. Roberts, T. M. de Reijke, S. Engelholm +5 more
2003115 citations Open access
Semantic Scholar
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.
F. Schröder, K. Kurth, S. Fosså, W. Hoekstra +3 more
2004Journal of Urology103 citations
Semantic Scholar
Adjusted significance levels for subgroup analyses in clinical trials.
B. Spiessens, M. Debois
2010Contemporary Clinical Trials89 citations
Semantic Scholar
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study
J. Pujol, T. De Pas, A. Rittmeyer, E. Vallières +15 more
2016Journal of Thoracic Oncology86 citations Open access
Semantic Scholar
Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001).
H. Van Poppel, K. Vekemans, L. Da Pozzo, A. Bono +4 more
2006European Journal of Cancer79 citations
Semantic Scholar
Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft I
Manfred P. Lutz, H. Wilke, D. J. Theo Wagener, U. Vanhoefer +10 more
2007Journal of Clinical Oncology73 citations
Semantic Scholar
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
F. Schröder, P. Whelan, T. M. de Reijke, K. Kurth +5 more
2004European Urology68 citations
Semantic Scholar
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non–Small-Cell Lung Cancer
J. Pujol, J. Vansteenkiste, T. De Pas, D. Atanackovic +14 more
2015Journal of Thoracic Oncology58 citations Open access
Semantic Scholar
Feasibility and risks of pre-operative chemotherapy (CT) with Folfox 4 and surgery for resectable colorectal cancer liver metastases (LM). Interim results of the EORTC Intergroup randomized phase III study 40983
B. Nordlinger, H. Sørbye, M. Debois, M. Praet +6 more
200556 citations
Semantic Scholar
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
M. Lutz, E. Van Cutsem, T. Wagener, J. Van Laethem +16 more
2005Journal of Clinical Oncology54 citations
Semantic Scholar
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
B. Nordlinger, P. Rougier, J. Arnaud, M. Debois +16 more
2005The Lancet Oncology53 citations
Semantic Scholar
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
M. Tapia, S. Sow, K. D. Mbaye, A. Thiongane +43 more
2020Lancet. Infectious Diseases (Print)49 citations Open access
Semantic Scholar
Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
M. Tapia, S. Sow, B. Ndiaye, K. D. Mbaye +46 more
2020Lancet. Infectious Diseases (Print)42 citations Open access
Semantic Scholar
Capecitabine plus irinotecan versus 5-FU/FA/irinotecan ± celecoxib in first line treatment of metastatic colorectal cancer (CRC). Long-term results of the prospective multicenter EORTC phase III study 40015.
J. De Grève, C. Koehne, J. T. Hartmann, István Láng +6 more
2005Journal of Clinical Oncology40 citations
Semantic Scholar
Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly: A phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment
P. Soubeyran, H. Khaled, M. Mackenzie, M. Debois +9 more
201133 citations
Semantic Scholar
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts
R. Nachbagauer, B. Salaun, D. Stadlbauer, M. A. Behzadi +13 more
2019npj Vaccines30 citations Open access
Semantic Scholar
Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983.
T. Gruenberger, H. Sørbye, M. Debois, U. Bethe +6 more
2006Journal of Clinical Oncology22 citations
Semantic Scholar
Platinum aluminophosphate oxynitride (Pt-AlPON) catalysts for the dehydrogenation of isobutane to isobutene
M. Centeno, M. Debois, P. Grange
200021 citations
Semantic Scholar
DRIFTS study of platinum aluminophosphate oxynitride catalysts
M. Centeno, M. Debois, P. Grange
199821 citations
Semantic Scholar
A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non–Small Cell Lung Cancer
B. Dizier, A. Callegaro, M. Debois, B. Dréno +16 more
2019Clinical Cancer Research16 citations Open access
Semantic Scholar
A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer
A. Clamp, P. Schöffski, J. Valle, Richard Wilson +7 more
2008Cancer Chemotherapy and Pharmacology16 citations
Semantic Scholar
A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
James E. Moon, Melissa E. Greenleaf, J. Regules, M. Debois +13 more
2021Vaccine14 citations Open access
Semantic Scholar
MAGRIT phase III trial: MAGE-A3 antigen-specific cancer immunotherapy (ASCI) as adjuvant therapy in patients with completely resected stage IB-IIIA NSCLC.
P. Therasse, J. Vansteenkiste, M. Zielinski, T. De Pas +15 more
2011Journal of Clinical Oncology9 citations
Semantic Scholar
MAGE-A3 GENE EXPRESSION FREQUENCY AND DEMOGRAPHY DATA OF STAGE IB-IIIA NSCLC PATIENTS FROM ONGOING MAGRIT PHASE III TRIAL EVALUATING MAGE-A3 ANTIGEN SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT TREATMENT
J. H. Kim, J. Jassem, H. Tada, M. Yoshimura +6 more
20108 citations
Semantic Scholar
PSA DOUBLING TIME AS PREDICTOR OF OBJECTIVE PROGRESSION AND DEATH IN PATIENTS WITH T0-4 N0-2 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL DEFINITIVE TREATMENT ON WATCHFUL WAITING (EORTC 30891)
L. Collette, U. Studer, P. Whelan, W. Albrecht +7 more
20067 citations
Semantic Scholar
19 WHICH SUBGROUPS OF PATIENTS WITH NEWLY DIAGNOSED TO-4 NO-2 MO PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT (EORTC 30891) ARE AT RISK TO DIE FROM PROSTATE CANCER AND BENEFIT FROM IMMEDIATE ANDROGEN DEPRIVATION?
U. Studer, L. Collette, P. Whelan, W. Albrecht +7 more
20076 citations
Semantic Scholar
Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01B vaccination.
O. Van Der Meeren, E. Jongert, K. Seaton, M. Koutsoukos +11 more
2020Vaccine5 citations Open access
Semantic Scholar
9021 Preliminary results of MAGE-A3 expression and baseline demographic data from MAGRIT, a large phase III trial of MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic) in adjuvant NSCLC
M. Zielinski, U. Laskowski, R. Bieselt, M. Reck +6 more
20095 citations
Semantic Scholar
IS THE DEGREE OF PSA DECLINE AFTER IMMEDIATE ANDROGEN DEPRIVATION A PROGNOSTIC FACTOR FOR OUTCOME IN PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT? (RESULTS FROM THE EORTC 30891 TRIAL)
L. Collette, U. Studer, P. Whelan, W. Albrecht +7 more
20065 citations
Semantic Scholar
303Patients with asymptomatic prostate cancer T.0-4 N.0-2 M.0 not suitable for local definitive treatment: Do they need immediate androgen deprivation?
U. Studer, P. Whelan, W. Albrecht, J. Casselman +7 more
20055 citations
Semantic Scholar
Immunogenicity and Safety of the Prame Cancer Immunotherapeutic in Non-Small Cell Lung Cancer (NSCLC): Phase I Dose Escalation Study
J. Pujol, T. De Pas, A. Rittmeyer, B. Kubisa +6 more
20124 citations Open access
Semantic Scholar
MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.
J. Pujol, J. Vansteenkiste, T. De Pas, D. Atanackovic +12 more
20124 citations
Semantic Scholar
MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized
T. De Pas, J. H. Kim, K. Zarogoulidis, M. Zielinski +11 more
20094 citations
Semantic Scholar
WHICH PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT DO NOT NEED IMMEDIATE TREATMENT IN EORTC TRIAL 30891?
L. Collette, U. Studer, P. Whelan, W. Albrecht +7 more
20064 citations
Semantic Scholar
1659: Immediate Versus Deferred Androgen Deprivation in Patients with Asymptomatic Prostate Cancer T0-4 N0-2 M0 Not Suitable for Local Definitive Treatment
U. Studer, P. Whelan, W. Albrecht, J. Casselman +7 more
20054 citations
Semantic Scholar
Non-small cell lung cancer, early stage
S. Peters, O. Dafni, L. Bubendorf, P. Meldgaard +108 more
20122 citations Open access
Semantic Scholar
382: Which Subgroups of Patients are at risk to die from Prostate Cancer and Benefit from Immediate Androgen Deprivation if they are not Suitable for local Treatment with Curative intent of Newly Diagnosed Prostate Cancer T0-4 N0-2 MO (EORTC 30891)?
U. Studer, L. Collette, P. Whelan, W. Albrecht +7 more
20072 citations
Semantic Scholar
Preliminary pharmacogenetic evaluation of toxicity data in the prospective multicentre EORTC trial 40015 in metastatic colorectal cancer (CRC).
D. Aust, C. Köhne, E. Goekkurt, J. De Grève +6 more
2006Journal of Clinical Oncology2 citations
Semantic Scholar
Sub-cellular Distribution of Hydrolytic Activities in the Rumen Ciliates Ophryoscolecidae
P. Hellings, M. Debois, P. Daubresse, D. Thinessempoux
19812 citations
Semantic Scholar
Cellulolytic System of Rumen Ciliates Ophryoscolecidae
P. Hellings, M. Debois, P. Daubresse, D. Thinessempoux
19821 citations
Semantic Scholar
DRIFTS Study of Pt-AIPON Catalysts
M. Centeno, M. Debois, P. Grange
20000 citations Open access
Semantic Scholar
Digital exchange of images and contours : radiological/oncological cooperation in radiotherapy planning for head and neck tumors
M. Feron, E. Bellon, H. Verstraete, R. Hermans +7 more
19970 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

L. Collette×14
Invite
L. Collette — researcher profile on SciRah
P. Whelan×10
Invite
P. Whelan — researcher profile on SciRah
T. M. de Reijke×10
Invite
T. M. de Reijke — researcher profile on SciRah
V. Brichard×9
Invite
V. Brichard — researcher profile on SciRah

×9

Invite

U. Studer — researcher profile on SciRah

Invite

W. Albrecht — researcher profile on SciRah

J. Casselman×9

Invite

J. Casselman — researcher profile on SciRah

Invite

W. Loidl — researcher profile on SciRah

Invite

S. Sundaram — researcher profile on SciRah

J. Vansteenkiste×8

Invite

J. Vansteenkiste — researcher profile on SciRah

Invite

T. De Pas — researcher profile on SciRah

Invite

S. Isorna — researcher profile on SciRah